Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03338296
Recruitment Status : Terminated (Study was terminated as Eisai agreed to voluntarily withdraw Belviq XR from US market.)
First Posted : November 9, 2017
Last Update Posted : February 12, 2021
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : March 30, 2020
Actual Study Completion Date : April 14, 2020
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 March 30, 2021
April 26, 2021 Submission with QC Comments